Cargando…
In silico studies of natural product-like caffeine derivatives as potential MAO-B inhibitors/AA(2A)R antagonists for the treatment of Parkinson's disease
Parkinson’s disease is considered the second most frequent neurodegenerative disease. It is described by the loss of dopaminergic neurons in the mid-brain. For many decades, L-DOPA has been considered as the gold standard for treating Parkinson’s disease motor symptoms, however, due to the decrease...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
De Gruyter
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9800045/ https://www.ncbi.nlm.nih.gov/pubmed/36112816 http://dx.doi.org/10.1515/jib-2021-0027 |